Approval · Notice of Compliance 885 · 2001
CLAVULIN: Notice of Compliance 885
Issued July 11, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 885
- Date
- July 11, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- Antibiotic and beta-lactamase inhibitor
Products in this notice
Medicinal ingredients
- CLAVULANATE POTASSIUM 125 MG per TAB
- AMOXICILLIN TRIHYDRATE 875 MG per TAB
- CLAVULANATE POTASSIUM 28.5 MG per 5ML
- AMOXICILLIN TRIHYDRATE 200 MG per 5ML
- CLAVULANATE POTASSIUM 57 MG per 5ML
- AMOXICILLIN TRIHYDRATE 400 MG per 5ML
- AMOXICILLIN TRIHYDRATE 250 MG per TAB
- AMOXICILLIN TRIHYDRATE 500 MG per TAB
- CLAVULANATE POTASSIUM 31.25 MG per 5ML
- AMOXICILLIN TRIHYDRATE 125 MG per 5ML
- CLAVULANATE POTASSIUM 62.5 MG per 5ML
- AMOXICILLIN TRIHYDRATE 250 MG per 5ML